PCDH17, protocadherin 17, 27253

N. diseases: 51; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 Biomarker disease BEFREE PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with BCP ALL. 27643535 2017
CUI: C0280141
Disease: Acute Undifferentiated Leukemia
Acute Undifferentiated Leukemia 		0.010 AlteredExpression disease BEFREE We identified protocadherin17 (PCDH17) and demonstrated that it was significantly down-regulated and hypermethylated in LSCs compared with HSCs. 30922328 2019
CUI: C0751606
Disease: Adult Acute Lymphocytic Leukemia
Adult Acute Lymphocytic Leukemia 		0.010 Biomarker disease BEFREE PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with BCP ALL. 27643535 2017
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.010 AlteredExpression disease BEFREE The risk allele predicted higher transcriptional levels of PCDH17 mRNA in postmortem brain samples, which is consistent with increased gene expression in patients with bipolar disorder compared with healthy subjects. 28070120 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 AlteredExpression disease BEFREE The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. 31772653 2019
CUI: C1305855
Disease: Body mass index
Body mass index 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. 27351130 2016
CUI: C0238301
Disease: Cancer of Nasopharynx
Cancer of Nasopharynx 		0.010 PosttranslationalModification disease BEFREE Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer. 30165032 2019
CUI: C0751571
Disease: Cancer of Urinary Tract
Cancer of Urinary Tract 		0.010 Biomarker disease BEFREE TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. 21847011 2011
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 PosttranslationalModification phenotype BEFREE These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs. 20200074 2010
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 AlteredExpression disease BEFREE The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. 31772653 2019
CUI: C1827293
Disease: Carcinoma of urinary bladder, invasive
Carcinoma of urinary bladder, invasive 		0.010 AlteredExpression disease BEFREE Furthermore, p53 mutation and low expression of PCDH17 were significantly associated with muscle-invasive bladder cancer. 31772653 2019
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.010 PosttranslationalModification disease BEFREE PCDH17 methylation was detected in almost 70% of HGSOC patients without any methylation in the group of control samples and was found both in the late stage tumors as well as in the early stage ones. 29991130 2018
CUI: C1449563
Disease: Cardiomyopathy, Familial Idiopathic
Cardiomyopathy, Familial Idiopathic 		0.010 AlteredExpression disease BEFREE <b>Conclusion</b>: Our study suggests that DCRF can act as a competing endogenous RNA to increase PCDH17 expression by sponging miR-551b-5p, thus contributing to increased cardiomyocyte autophagy in DCM. 31285779 2019
CUI: C0023452
Disease: Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia 		0.010 Biomarker disease BEFREE PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with BCP ALL. 27643535 2017
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 AlteredExpression disease BEFREE We previously identified PCDH17, encoding protocadherin 17, as a frequently methylated and downregulated tumor suppressor gene (TSG) in gastric and colorectal cancers. 27351130 2016
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 Biomarker disease BEFREE Our previous study showed that the protocadherin 17 (<i>PCDH17</i>) gene was frequently methylated and functioned as a tumor suppressor in CRC. 31815010 2019